Abstract. The objective of the present study was to investigate the association between recurrent implantation failure (RIF) and vascular endothelial growth factor (VEGF) gene polymorphisms that are associated with various female infertility disorders. A total of 116 women diagnosed with RIF and 218 control subjects were genotyped for the VEGF -2578C>A, -1154G>A, -634C>G and 936C>T polymorphisms using a polymerase chain reaction-restriction fragment length polymorphism assay. The VEGF -2578AA genotype was associated with an increased prevalence (≥4) of RIF [adjusted odds ratio (AOR)=2.77; 95% confidence interval (CI)=1.10-7.02; P=0.031], whereas the VEGF -634CG+GG genotype was associated with an increased incidence of total RIF (AOR=2.03; 95% CI=1.02-4.05; P=0.044) and ≥4 RIF (AOR=3.16; 95% CI=1.19-8.37; P=0.021). The results of the haplotype analysis indicated that -2578A/-1154A/-634G/936C (AOR=1.76; 95% CI=1.03-3.00; P=0.040 for total RIF and AOR=2.11; 95% CI=1.12-3.97; P=0.021 for ≥4 RIF) was associated with the occurrence of RIF. In addition, it was revealed that there was a significant difference in serum prolactin level associated with the VEGF -634C>G polymorphism (P=0.013). Therefore the findings of the present study indicate that the VEGF -2578AA genotype, -634G allele and -2578A/-1154A/-634G/936C haplotype may be genetic markers for susceptibility to RIF. However, further studies on VEGF promoter polymorphisms that include an independent randomized-controlled population are required to confirm these results.
Introduction
Recurrent implantation failure (RIF) refers to when an implanted embryo repeatedly fails to result in the development of an intrauterine gestational sac following embryo transfer (ET), as determined by ultrasonography (1) . RIF may simply be defined as two or more continuous implantation failures (2) ; however, researchers now prefer to define RIF as the failure to maintain a clinical pregnancy following three cycles of ET (3, 4) . Several causes of RIF have been reported, including embryo, uterine and immunological factors, as well as thrombophilic conditions, however, the genetic mechanisms underlying RIF remain unclear (1) .
Embryo implantation is a multifactorial event that depends on the interaction of the blastocyst with the receptive endometrium and consists of molecular signaling by the embryo, followed by apposition and attachment to the endometrium (5) . Following the formation of the fetal-maternal interface, the essential second step involves the invasion of the embryo endometrium (6) . This invasion induces endometrial angiogenesis, which is promoted by numerous growth factors, including vascular endothelial growth factor (VEGF). VEGF increases vascular permeability and activates endothelial cell proliferation, migration, differentiation and capillary formation (6) . The intrauterine concentrations of VEGF during the menstrual cycle were determined in women experiencing infertility and it was revealed that VEGF concentrations are cycle-dependent and increase during the late secretory and premenstrual phases (7) . VEGF concentrations are also correlated with levels of insulin-like growth factor-binding protein 1, the decidualization marker of the endometrium (8) . Sugino et al (9) examined the expression of VEGF and its receptors throughout the menstrual cycle and in early pregnancy. The Association between vascular endothelial growth factor promoter polymorphisms and the risk of recurrent implantation failure results revealed that the expression of VEGF and its receptor were higher in the mid-secretory phase compared with the proliferative phase during normal menstrual cycles. There was also a marked expression of VEGF in decidual cells in early pregnancy. The authors concluded that VEGF contributes to the successful implantation and maintenance of pregnancy by increasing vascular permeability or by forming the vascular network in the decidua. Kapiteijn et al (10) cultured human embryos in VEGF-conditioned media as an in vitro model and demonstrated that VEGF induced endometrial angiogenesis in the embryos. The results of these previous studies indicate that VEGF may be a key regulator in angiogenesis and decidualization of the endometrium, which are essential processes for the maintenance of a successful pregnancy. VEGF is located on chromosome 6p21.3 and is comprised of eight exons (11) . Several single nucleotide polymorphisms (SNPs) have been previously detected in VEGF, including -2578C>A, -1154G>A, -634C>G and 936C>T, which are associated with altered VEGF expression (12) (13) (14) (15) (16) . There have been several previous reports that VEGF polymorphisms are associated with the development and prognosis of a variety of obstetrical and gynecological diseases (17) (18) (19) . Additionally, there have been reports that the VEGF -1154G>A and -634C>G polymorphisms are associated with the occurrence of RIF (20) (21) (22) (23) , however, only a small number of studies have evaluated the association between other functional VEGF polymorphisms and the incidence rate of RIF (24, 25) .
The objective of the present study was to examine whether single VEGF SNPs or the functional VEGF polymorphism haplotype -2578C>A (rs699947), -1154G>A (rs1570360), -634C>G (rs2010963) and 936C>T (rs3025039) may affect the susceptibility to RIF in Korean females. In the present study, RIF was defined as the failure to achieve pregnancy following the completion of two fresh in vitro fertilization-ET cycles with >10 cleaved embryos and serum human chorionic gonadotrophin concentrations <5 U/ml 14 days after ET. All embryos were examined by an embryologist prior to transfer and judged to be of a good quality. The male and female partner in each couple experiencing RIF was evaluated. Subjects who were diagnosed with RIF due to anatomical, chromosomal, hormonal, infectious, autoimmune or thrombotic causes were excluded from the present study. Anatomical abnormalities were evaluated using several imaging modalities, including sonography, hysterosalpingogram, hysteroscopy, computerized tomography and magnetic resonance imaging. Karyotyping was conducted using standard protocols to assess chromosomal abnormalities (26, 27) . Hormonal causes of RIF, including hyperprolactinemia, luteal insufficiency and thyroid disease were excluded by measuring the concentrations of prolactin (PRL), thyroid-stimulating hormone (TSH), free thyroxine, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and progesterone in samples of peripheral blood. Lupus anticoagulant and anticardiolipin antibodies were examined according to the protocols of a previous study (28) to exclude lupus and antiphospholipid syndrome as autoimmune causes of RIF. Thrombotic causes of RIF were defined as thrombophilia and were evaluated by the detection of protein C and S deficiencies and by the presence of anti-α2 glycoprotein antibodies using methods described in a previous study (29) .
Materials and methods

Study
The enrollment criteria for the control group included regular menstrual cycles, normal karyotype (46, XX), a history of at least one naturally conceived pregnancy and no history of pregnancy loss, including abortion. Data collection methods for each group were identical.
The study protocol was approved by the Institutional Review Board of CHA Bundang Medical Center on 23 February 2010 (reference no. CHAMC2009-12-120). All study participants provided written informed consent prior to participating in the present study. All the methods applied in the study were performed in accordance with the approved guidelines.
Hormone assays. Blood samples were collected by venipuncture on day 2 or 3 of the menstrual cycle for the measurement of FSH, LH, E2, TSH and PRL levels. Serum was prepared as previously described (30) and hormone levels were determined using either radioimmunoassays [E2 (cat. no., A21854), TSH (cat. no., IM3712) and PRL (cat. no., IM2121); Beckman Coulter, Inc., Brea, CA, USA], or enzyme immunoassays using IMMULITE ® 1000 Systems (FSH and LH; Siemens AG, Munich, Germany) according to the manufacturer's protocol.
Genotype analysis. Genomic DNA was extracted from whole blood using the G-DEX IIc Genomic DNA Extraction kit (Intron Biotechnology Inc., Seongnam, Korea) and purified using the high-salt buffer method (31) . DNA was diluted to 100 ng/µl with 1X TE (Tris-EDTA) buffer and subsequently 1 µl from each sample was used to amplify VEGF polymorphisms. Genotyping was performed by polymerase chain reaction (PCR) restriction fragment length polymorphism using the following primers: VEGF -2578C>A polymorphism forward, 5'-GGA TGG GGC TGA CTA GGT AAG-3' and reverse, 5'-AGC CCC CTT TTC CTC CAA C-3' to generate a 308-bp (C allele) or 326-bp (A allele) product; VEGF -1154G>A polymorphism forward, 5'-CGC GTG TCT CTG GAC AGA GTT TCC-3' and reverse, 5'-CGG GGA CAG GCG AGC TTC AG-3' to generate a 173-bp (A allele) or 141-bp (G allele) product; VEGF -634C>G polymorphism forward, 5'-CAG GTC ACT CAC TTT GCC CCG GTC-3' and reverse, 5'-GCT TGC CAT TCC CCA CTT GAA TCG-3' to generate a 204-bp (C allele) or 180-bp (G allele) product; VEGF 936C>T polymorphism forward, 5'-AAG GAA GAG GAG ACT CTG CGC AGA GC-3' and reverse, 5'-TAA ATG TAT GTA TGT GGG TGG GTG TGT CTA CAG G-3' to generate a 208-bp (C allele) or 122-bp (T allele) fragment. The thermocycling conditions for each set of primers are presented in Table I and all PCR experiments were performed using an AccuPower ® HotStart PCR PreMix (Bioneer Corporation, Daejeon, Korea). VEGF polymorphisms were identified by digesting the VEGF -2578C>A and -634G>C PCR products with the AvaII restriction endonuclease (New England BioLabs, Inc., Ipswich, MA, USA) and the VEGF -1154G>A and 936C>T PCR products with MnlI and NlaIII restriction endonucleases (New England BioLabs, Inc., Ipswich, MA, USA). All restriction digests were performed at 37˚C for 16 h and detected using gel electrophoresis with 3% agarose gel and visualized with ethidium bromide on a Gel-Doc XR+ version system (Bio-Rad, Hercules, CA, USA).
Statistical analysis. Differences in the genotype and haplotype frequencies between RIF subjects and controls were compared using multivariate logistic regression. Allelic frequencies were calculated to identify deviations from Hardy-Weinberg equilibrium (HWE), using P<0.05 as the significance threshold as previously described (32, 33) . Adjusted odds ratios (AORs) and 95% confidence intervals (CI) were used to measure the strength of the association between different genotypes and RIF. Association analysis was performed among groups that were stratified by implantation failure number. Patients with RIF were defined as those with ≥2 implantation failures and patients were divided into the following groups: Total RIF, ≥3 implantation failures (≥3 RIF) and ≥4 implantation failures (≥4 RIF). As there was no significant difference between the ≥3 RIF group and the total RIF group, the ≥4 RIF group was compared with the total RIF group. P<0.05 was considered to indicate a statistically significant difference. Differences in hormone concentrations (E2, FSH, LH, PRL and TSH) in accordance with VEGF genotypes and alleles were evaluated using a one-way analysis of variance with a post-hoc Scheffé test for all pairwise comparisons and independent two-sample t-tests as appropriate. Data are presented as the mean ± standard deviation. Statistical analyses were performed using GraphPad Prism version 4.0 (GraphPad Software, Inc., La Jolla, CA, USA), StatsDirect version 2.4.4 (StatsDirect Ltd., Altrincham, UK) and PLINK version 1.07 (http://zzz.bwh.harvard.edu/plink/). Statistical power was calculated using the G*Power program version 3.1.7 (http://www.gpower.hhu.de/).
Transcription factor binding site prediction. The DNA sequence of the VEGF promoter was used to predict transcription factor binding sites. The P-Match (http://www.gene-regulation.com) (34, 35) was used to predict the transcription factors that would bind to the region in VEGF promoter. P-Match is interconnected with the TRANSFAC ® database (http://gene-regulation.com/).
Results
Baseline characteristics and the frequency of VEGF polymorphisms.
The demographic characteristics of the study participants are presented in Table II . Patient age and RIF was matched with the relevant control groups and the following characteristics were examined: Age, BMI, gestational age and hormone levels including estradiol, FSH, LH, TSH and PRL. The results demonstrated that there were no significant differences in RIF between patients with RIF and controls. The genotypic distribution and haplotype frequencies of VEGF -2578C>A, -1154G>A, -634C>G and 936C>T for all study participants are detailed in Table III . The HWE was observed for all VEGF polymorphic sites analyzed in each group. The frequencies of the VEGF -2578CC, -1154GG, -634CC and 936CC genotypes corresponding to the reference genotypes of the four polymorphisms were 51.4, 72.0, 18.8 and 69.3% in the control group and 48.3, 67.2, 10.3 and 67.2% in the RIF group. Furthermore, the frequency of the VEGF -2578C/-1154G/-634C/936C haplotype was 42.0% in the control group and 31.9% in the RIF group. In the present study, patients with RIF exhibited higher frequencies of the VEGF variant genotypes and haplotypes, leading to an increased number of implantation failures, compared with controls.
Genetic susceptibility of single and multiple markers. The AORs for RIF prevalence according to the VEGF genotypes are provided in Table IV . The VEGF -2578AA genotype was associated with a significantly increased prevalence (≥4) of RIFs (AOR=2.77; 95% CI=1.10-7.02; P=0.031). The VEGF -634CG+GG genotype was associated with a significantly increased incidence of total RIF (AOR=2.03; 95% CI=1.02-4.05; P=0.044) and ≥4 RIFs (AOR=3.16; 95% CI=1.19-8.37; P=0.021). No statistically significant differences were observed between the control and RIF groups for any of the other genotypes.
The linkage disequilibrium of the VEGF polymorphisms at loci -2578(rs699947)/-1154(rs1570360)/-634 (rs2010963)/936(rs3025039) in the RIF and control groups are detailed in Fig. 1 . There was a clear linkage disequilibrium between loci -1154 and -634 (D'=0.945) and -2578 and -634 (D'=0.885) in the control group (Fig. 1A) . Polymorphisms -1154G>A and -634G>C had a clear linkage disequilibrium in the RIF group (D'=1.000; Fig. 1B) . The selected haplotypes with the four VEGF polymorphisms were constructed to determine if any specific haplotypes were associated with RIF prevalence (Table IV) . The C-G-G-C (AOR=1.59; 95% CI=1.06-2.39; P=0.026 for total RIF and AOR=2.00; 95% CI=1.23-3.26; P=0.006 for ≥4 RIF), C-G-G-T (AOR=2.29; 95% CI=1.10-4.79; P=0.027 for total RIF) and A-A-G-C (AOR=1.76; 95% CI=1.03-3.00; P=0.040 for total RIF and AOR=2.11; 95% CI=1.12-3.97; P=0.021 for ≥4 RIF) haplotype frequencies of the VEGF -2578C>A, -1154G>A, -634C>G and 936C>T variants, respectively, were significantly different between the RIF and the control group.
Differences in hormones according to VEGF polymorphisms in the RIF group. Possible associations between RIF and the serum level of PRL were examined. The results are presented in Fig. 2 according to VEGF gene polymorphisms. Patients with the VEGF -634GG genotype had significantly lower serum PRL levels compared with patients with the VEGF -634CC genotype ( Fig. 2A) . Additionally, patients with the VEGF -634G allele had significantly lower serum PRL levels compared with patients with the VEGF -634C allele (Fig. 2B) . Levels of the other hormones investigated (E2, FSH, LH and TSH) were not significantly associated with the polymorphisms examined in the present study (Table V) . Table VI summarizes the statistical power of genetic associations in the present case-control study. The analysis of VEGF -634C>G polymorphism was statistically significant when compared with the additive model (94.49%), dominant model (99.91%) and recessive model (94.79%) for AORs with RIF risk in total RIFs. In ≥4 RIFs, the statistical power of VEGF -634C>G polymorphism was strongly significant when compared with the additive model (99.25%), dominant model (100%) and recessive model (99.85%). In addition, the VEGF -2578C>A polymorphism was demonstrated to possess a greater statistical power than that of the recessive model (99.99%) in AORs of ≥4 RIFs.
Discussion
The present study evaluated the association between four functional VEGF SNPs (-2578C>A, -1154G>A, -634C>G and 936C>T) and the prevalence of RIF in Korean females. The results indicated that the VEGF -2578AA genotype, -634G allele and -2578C/-1154G/-634G/936C, -2578C/-1154G/-634G/936T and -2578A/-1154A/-634G/936C haplotypes may be genetic markers for susceptibility to RIF. The -2578C>A and -1154G>A variants are located in the VEGF promoter region (26) . The VEGF -2578CC and -1154GG genotypes appear to confer increased VEGF secretion compared with the presence of a minor allele (36, 37) . However, the functional effect of VEGF -634C>G is contested. Watson et al (15) and Hansen et al (38) proposed that the VEGF -634C allele was associated with the decreased production of VEGF, whereas Wongpiyabovorn et al (16) and Awata et al (39) reported that the VEGF -634G allele was associated with decreased VEGF production. These conflicting results are potentially due to the effect of haplotype combinations. Therefore, based on the VEGF haplotypes containing other VEGF SNPs, the effect of VEGF -634C>G should be examined further. It has previously been reported that there is an association between the haplotypes resulting from polymorphisms in the promoter region (-2578/-1154/-634) and VEGF expression (36). Lambrechts et al (36) reported that the -2578A/-1154A/-634G and -2578A/-1154G/-634G VEGF haplotypes were significantly correlated with decreased VEGF mRNA expression and plasma concentrations. Among these polymorphisms, the mechanism of VEGF -2578C>A is well known (36, 40, 41) . This SNP is in complete linkage with the deletion/insertion of an 18-bp fragment in the -2549 region and a construct containing the 18-bp deletion (linkage with the C allele) causing a 1.95-fold increase in transactivation (42) . As evidence of the VEGF -1154G>A and -634C>G function is limited, the transcription factor binding sites containing these SNPs were predicted using P-Match. VEGF-1154G>A is contained within a predicted binding site for myeloid zinc finger-1 (MZF1) in which the MZF1 binding site is substituted for the Pax2 or Sp1 binding site by -1154A (prediction data attained using P-Match; gene-regulation. com). VEGF -634C>G is likewise identified within the predicted MZF1 or Pax2 binding site (prediction data attained False discovery rate-adjusted P-value for multiple hypotheses testing using the Benjamini-Hochberg method. AOR, adjusted odds ratio; CI, confidence intervals; RIF, recurrent implantation failure; NA, not applicable; VEGF, vascular endothelial growth factor. AORs and P-values were adjusted by age and body mass index. using P-Match; gene-regulation.com), however, a change in the predicted transcription factor binding sites is not produced by the substitution.
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In addition to VEGF, serum levels of the classical decidualization marker PRL should also be considered in association with decidualization of the endometrium. The present study revealed an association between the VEGF -634C>G polymorphism and plasma PRL levels. A previous study reported that VEGF rs3025039C>T was correlated with plasma PRL levels in polycystic ovary syndrome (43) . A number of previous studies have also revealed that secreted PRL affects tissue vascularization at the lactation stage and present a role of PRL as a pro-angiogenic factor (44) (45) (46) (47) (48) . Based on this, the current authors hypothesized that VEGF polymorphisms may affect the plasma PRL levels, however this hypothesis was not clearly confirmed or rejected through the experiments of the present study. Therefore, further studies are necessary to determine the potential association between VEGF polymorphisms and PRL levels.
Furthermore, previous studies have demonstrated that differences in PRL levels affect the formation of the placenta and decidualization of the endometrium following fertilization (44, (49) (50) (51) (52) . PRL also regulates inflammatory cytokine (TNF-α, IL-1α, IL-1β, TGF-β and IL-8) levels and immune system homeostasis in early pregnancy (53) (54) (55) . Therefore, normal PRL levels are critical for maintaining a successful pregnancy. In addition, PRL regulates gonadal function and serves roles in steroidogenesis, formation of the corpus luteum and modulation of the effects of gonadotropins (55) . PRL stimulates the process of ovulation, implantation and placental development (49) (50) (51) (52) 56) . In addition, PRL stimulates the growth, development and metabolism of the fetus, serves key roles in the formation of the corpus luteum, decreases levels of sex steroids during the menstrual cycle and stimulates the production of milk during the postpartum period (57) .
The present study had several limitations. Firstly, the serum VEGF levels in the participants were not measured. Although the association between VEGF polymorphisms and serum VEGF levels has been elucidated in other conditions (36, 42) , the data associated with RIF is limited. Secondly, it was not possible to explain the exact role of VEGF in the pathogenesis of RIF development. Accordingly, in future research an association between the VEGF polymorphisms and VEGF expression in the tissues in which implantation events occur, as opposed to serum concentrations, should be elucidated. VEGF expression occurs within biochemical pathways and is not the only risk factor for disorders associated with implantation and pregnancy maintenance. Therefore, the interactions between VEGF and other factors expressed during implantation are also potential risk factors. To overcome these constraints, further studies on the functional role of VEGF polymorphisms in the pathogenesis of RIF are required. Estradiol (pg/ml) FSH (mIU/ml) LH (mIU/ml) PRL (ng/ml) In conclusion, the -2578C>A, -1154G>A and -634C>G polymorphisms in the VEGF promoter region were associated with the occurrence of RIF. The results revealed an association between the VEGF -634C>G polymorphism and serum PRL levels. However, further studies of the VEGF promoter polymorphisms involving an independent randomized-controlled population are required to confirm these results. Additionally, the results of the present study warrant additional studies to elucidate the functional role of VEGF promoter polymorphisms in the RIF etiologies. Therefore, the present study indicates that the VEGF -2578AA genotype, -634G allele and -2578A/-1154A/-634G/936C haplotype may be utilized as biomarkers for patients with RIF. However, further studies are required to confirm this.
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